Clinical trial · Expanded Access
Master Rollover Protocol for Continued Safety Assessment of Study Drug
NCT02632994CI-TRIAL-00115848availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY2503029 | Drug | — | UNRESOLVED |
| LY3023414 | Drug | Samotolisib | ALIAS |
| LY3838915 | Drug | — | UNRESOLVED |
| LY3847429 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol. Exclusion Criteria: * Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
References
Publications (0)
Data not yet available
No reference posted for this study.